Ilyssa

Drospirenone/Ethinylestradiol, the active ingredient in Ilyssa, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy and can help regulate menstrual cycles in women of reproductive age. Ilyssa is marketed in the European Union and complies with relevant regulatory standards for hormonal contraceptives.

GNH USA supplies Ilyssa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilyssa, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle.

Contraception: provides effective prevention of pregnancy when taken as directed. Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. Management of acne: may improve acne associated with androgen excess in women.

Ilyssa may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset that often resolves with continued use. - Headache: occasional tension‑type or migraine‑type headaches. - Breast tenderness: temporary swelling or discomfort. - Breakthrough bleeding: spotting between periods, especially during the first months. - Weight fluctuation: minor changes in fluid retention. - Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Hypertension: significant increase in blood pressure. - Liver dysfunction: abnormal liver enzyme levels or jaundice. - Allergic reaction: rash, swelling, or difficulty breathing. - Gallbladder disease: rare occurrence of gallstones or inflammation.

Before prescribing Ilyssa, clinicians should assess individual risk factors and contraindications.

Cardiovascular risk assessment: evaluate history of thrombosis, smoking, or hypertension. Pregnancy status: confirm the patient is not pregnant before initiating therapy. Liver disease: avoid use in active liver disease or severe hepatic impairment. Migraine with aura: contraindicated in patients with migraine accompanied by neurological symptoms. Age >35 and smoking: contraindicated for women over 35 who smoke. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ilyssa can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Rifampin and other potent enzyme inducers: can markedly decrease hormone levels. - Certain HIV protease inhibitors: may increase hormone concentrations, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase hormone levels. - St. John’s wort: may modestly reduce contraceptive efficacy. - Certain antibiotics (e.g., clarithromycin): potential modest effect on hormone metabolism. - Diuretics: may affect fluid balance and blood pressure, requiring monitoring.